Short answer
GeneDx Holdings Corp. (WGS) filed its Q2 2026 10-Q quarterly report on Aug 3, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $114M (up 11.4% year over year) with net income of −$18M.
Q2 2026 key financials · XBRL
- Revenue
- $114M
- +11.4% YoY · +11.9% QoQ
- Net income
- −$18M
- −264.1% YoY · +72.0% QoQ
- Operating margin
- -15.3%
- Gross margin
- 68.4%
- EPS (diluted)
- −$0.59
- −259.5% YoY · +72.7% QoQ
Source: XBRL data from the GeneDx Holdings Corp. (WGS) Q2 2026 10-Q on SEC EDGAR. USD.
GeneDx Holdings Corp. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $114.4M, up 11% YoY from $102.7M
- Gross margin 68.4% vs 69.0% YoY; adjusted gross margin 70.4% vs 70.6%
- Whole exome and genome revenue up 17%, driven by 32% higher test volumes; average reimbursement rates down 12%
- Net loss $17.7M vs $10.8M net income; operating loss $17.5M vs $9.0M income
- Cash, equivalents and marketable securities $132.5M; sufficient liquidity for at least twelve months, with reimbursement and payor denials remaining headwinds
Risk Factors
- Newly added securities-litigation risk: lawsuits filed June 4 and July 28, 2026 after stock-price volatility
- Legal exposure: complaints cover securities purchases from April 16, 2025 through May 4, 2026
- Market risk: life-sciences valuations may remain volatile independent of operating performance
- Financing risk: declining share price could impair future equity issuance and financing access
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other GeneDx Holdings Corp. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.